Mayank Mittal, MD
Interventional Cardiology · South Bend, INNPI 1003044702
Payments from drug & device makers
Across 568 payments — averaging $75.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$14K
- Abbott$6K
- E.r. Squibb & Sons, L.L.C.$4K
- Edwards Lifesciences$4K
- Cardiovascular Systems Inc.$3K
- Abiomed$3K
- plus $10K from 34 others
What the payments were for
- Speaking & faculty fees$9,08021%
- Travel & lodging$14,23433%
- Food & beverage$18,97844%
- Education$4611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 109 | $14,126 |
| Abbott | 72 | $5,660 |
| E.r. Squibb & Sons, L.L.C. | 16 | $4,408 |
| Edwards Lifesciences | 29 | $3,582 |
| Cardiovascular Systems Inc. | 31 | $2,699 |
| Abiomed | 38 | $2,641 |
| Medtronic(2 entities) | 39 | $2,233 |
| Shockwave Medical, Inc | 29 | $1,407 |
| Baylis Medical Company Inc | 2 | $1,350 |
| Novartis | 65 | $1,024 |
| W. L. Gore & Associates, Inc. | 6 | $691 |
| Cardiva Medical, Inc. | 9 | $384 |
| Johnson & Johnson | 35 | $326 |
| Amgen | 8 | $249 |
| Sanofi-aventis U.S. LLC | 3 | $213 |
| Pfizer | 12 | $200 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $196 |
| Penumbra, Inc. | 7 | $163 |
| Amarin Pharma, Inc. | 5 | $158 |
| Boehringer Ingelheim | 9 | $146 |
| Cvrx, Inc. | 3 | $137 |
| Reflow Medical Inc | 1 | $93 |
| Heartflow, Inc. | 3 | $86 |
| Actelion Pharmaceuticals US, Inc. | 2 | $86 |
| Philips North America LLC | 3 | $65 |
| AstraZeneca | 4 | $61 |
| Covidien LP | 1 | $46 |
| Biosense Webster, Inc. | 2 | $44 |
| Cordis US CORP. | 2 | $34 |
| Surmodics, Inc. | 1 | $33 |
| Inari Medical, Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Merck | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| GSK | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Teleflex LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$5,781
- CAMZYOS$4,204
- Watchman$3,067
- Peripheral Orbital Atherectomy System$2,025
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,579
- WATCHMAN FLX$1,487
- AMPLATZER$1,445
- NRG needle$1,350
- MitraClip System$1,142
- CoreValve Evolut$1,123
- GENERAL - THERAPIES$916
- THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM$739
- MitraClip$654
- GORE CARDIOFORM Septal Occluder$630
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$576
- SAPIEN 3 Ultra RESILIA$436
- AMPLATZER AMULET$432
- CROSSBOSS$411
- GENERAL VASCULAR ACCESS$302
- Impella$237
How this compares
$42,754 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 250 | $259,990 |
| EntrestoSacubitril/Valsartan | 117 | $155,843 |
| XareltoRivaroxaban | 67 | $72,786 |
| JardianceEmpagliflozin | 45 | $58,681 |
| BrilintaTicagrelor | 35 | $32,486 |
| Repatha SureclickEvolocumab | 13 | $15,970 |
| Ranolazine ErRanolazine | 57 | $8,268 |
| Repatha SyringeEvolocumab | 14 | $7,838 |
| Atorvastatin Calcium | 479 | $4,405 |
| Metoprolol Succinate | 364 | $4,172 |
| ClopidogrelClopidogrel Bisulfate | 360 | $3,599 |
| Prasugrel Hcl | 22 | $3,030 |
| Ezetimibe | 150 | $2,456 |
| Rosuvastatin Calcium | 195 | $2,321 |
| Digoxin | 30 | $2,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $200 | $259,990250 claims |
| NovartisEntresto | $1,024 | $155,843117 claims |
| Johnson & JohnsonXarelto | $326 | $72,78667 claims |
| Boehringer IngelheimJardiance | $146 | $58,68145 claims |
| AstraZenecaBrilinta | $61 | $32,48635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in South Bend
- Khalid NajibSouth Bend$26K
- Muhammad AslamSouth Bend$19K
- Waseem BarhamSouth Bend$13K
- James HermillerIndianapolis$2.8M
- Jithendra ChoudaryRichmond$1.6M
- Jeffrey BreallIndianapolis$955K
- Samer AbbasEast Chicago$625K
- Jarrod FrizzellEvansville$559K
- Brian BigelowIndianapolis$444K
- Saeed ShaikhIndianapolis$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.